Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409899 | 0.77 | PLAU (0.43) | ALDH1A1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL10367814 | 0.73 | MTNR1A (0.38) | VSIRALDH1A1MAPTPTPRCLATS1 | |
| SCHEMBL5201034 | 0.73 | VSIR (0.38) | VSIRALDH1A1MAPTPTPRCLATS1 | |
| SCHEMBL30931594 | 0.73 | GRM2 (0.35) | ALDH1A1STK17BSTK17AMEN1KMT2A | |
| SCHEMBL21392140 | 0.71 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30937609 | 0.71 | MAPKAPK2 (0.43) | VSIRMAPTMAPKAPK2 | |
| SCHEMBL5004498 | 0.70 | ALDH1A1 (0.36) | VSIRALDH1A1MAPTPTPRCLATS1 | |
| SCHEMBL16355717 | 0.70 | VSIR (0.50) | VSIRCCNT1MAPTPTPRCLATS1 | |
| SCHEMBL3409879 | 0.69 | MEN1 (0.47) | ALDH1A1GLASTK17BSTK17AMEN1 | |
| SCHEMBL1227911 | 0.69 | GAA (0.53) | ALDH1A1MAPTS1PR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | VSIR 4412/4885ALDH1A1 2956/4885CCNT1 3574/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | VSIR 4482/4885ALDH1A1 2860/4885CCNT1 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.